Renal ablation in patients with end-stage renal disease

VASA ◽  
2011 ◽  
Vol 40 (4) ◽  
pp. 308-314 ◽  
Author(s):  
Hansch ◽  
Pfeil ◽  
Neumann ◽  
Neumann ◽  
Mayer ◽  
...  
Keyword(s):  
Nephrotic Syndrome ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Uncontrolled Hypertension ◽  
Reactive Protein ◽  
Renal Embolization ◽  
Renal Ablation ◽  
Typical Finding ◽  
Stage Renal Disease ◽  
End Stage

Background: Transarterial catheter embolization of the kidneys (TAE) is a minimally invasive, image-guided procedure. In this study outcome and TAE-related complications of the patients who underwent TAE of the kidneys were evaluated retrospectively. Patients and methods: Between August 2003 and August 2009, 11 patients underwent selective percutaneous transarterial renal embolization for end stage renal disease associated with uncontrolled hypertension, nephrotic syndrome, bleeding or malignancy. TAE of renal arteries was performed using different embolization agents. Results: Successful renal embolization was possible in all 21 kidneys. All patients became anuric. Non-target embolization was not detectable. Nevertheless, all patients developed some degree of postembolization symptoms including nausea, vomiting, fever or pain. A typical finding after embolization was an increase in the C-reactive protein Conclusions: Renal embolization is rarely done but should be considered as an alternative to surgical nephrectomy in patients with end stage renal disease due to the lesser invasiveness. Our study confirms the safety and effectivity of percutaneous renal embolization in patients with ESRD. We were able to control the hypertension, nephrotic syndrome, and bleeding caused by ESRD.

Serum albumin, inflammation, and nutrition in end-stage renal disease: C-reactive protein is needed for optimal assessment

2018 ◽  
Vol 31 (5) ◽  
pp. 435-439 ◽  
Author(s):  
Hideyuki Mukai ◽  
Hilda Villafuerte ◽  
Abdul Rashid Qureshi ◽  
Bengt Lindholm ◽  
Peter Stenvinkel
Keyword(s):  
Renal Disease ◽  
Serum Albumin ◽  
End Stage Renal Disease ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Stage Renal Disease ◽  
End Stage

C‐reactive protein levels are associated with periodontitis and periodontal inflamed surface area in adults with end‐stage renal disease

2020 ◽  
Author(s):  
Caroline Schöffer ◽  
Leandro Machado Oliveira ◽  
Samantha Simoni Santi ◽  
Raquel Pippi Antoniazzi ◽  
Fabricio Batistin Zanatta
Keyword(s):  
Renal Disease ◽  
Surface Area ◽  
End Stage Renal Disease ◽  
C Reactive Protein ◽  
Protein Levels ◽  
Reactive Protein ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals CUT OFF VALUE OF PROCALCITONIN IN END STAGE RENAL DISEASE PATIENTS WITHOUT INFECTION

2021 ◽  
Vol 5 (02) ◽  
Author(s):  
Naila Asif ◽  
Samina Shamim ◽  
Shafqat Waqar Khanzada ◽  
Muhammad Rizwan
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Serum Levels ◽  
Acute Phase Reactant ◽  
Normal Serum ◽  
Maintenance Hemodialysis ◽  
Maintenance Haemodialysis ◽  
Reactive Protein ◽  
Stage Renal Disease ◽  
End Stage

OBJECTIVE: To determine cut off value of procalciton (PCT) in aseptic end stage renal disease patients undergoing haemodialysis. BACKGROUND: Haemodialysisis considered as a proinflammatory state and therefore associated with release of inflammatory cytokines and acute phase reactant proteins. The conventional laboratory markers (C-reactive protein, erythrocyte sedimentation rate) are efficient tools for the diagnosis of infection in patients with normal kidney functions. However they can be nonspecifically elevated in patients on haemodialysis and only reflect inflammatory response not associated with infection. PCT is considered a very important biomarker in differentiating infections from inflammation. The study was undertaken to evaluate normal serum levels of PCT in patients undergoing HD.PATIENTS AND METHOD: The study included 82 end-stage renal failure patients without evidence of systemic or localized infection undergoing maintenance haemodialysis. RESULTS: In our study, the PCT concentrations showed a mean of .622ng/ml in patients on maintenance hemodialysis without signs of infection. CONCLUSION:The study suggests that serum PCT at a cutoff value of .62ng/ml should be considered normal in aseptic haemodialysis patients. KEYWORDS: Procalcitonin, haemodialysis, sepsis

scholarly journals A case report of congenital nephrotic syndrome caused by new mutations of NPHS1

2021 ◽  
Vol 49 (8) ◽  
pp. 030006052110381
Author(s):  
Zhong Li ◽  
Lanchun Zhuang ◽  
Mei Han ◽  
Feng Li
Keyword(s):  
Nephrotic Syndrome ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Treatment Plan ◽  
Congenital Nephrotic Syndrome ◽  
Immunosuppressive Drugs ◽  
Normal Function ◽  
Heterozygous Mutation ◽  
Stage Renal Disease ◽  
End Stage

Congenital nephrotic syndrome (CNS) is a rare autosomal recessive disorder that occurs in the first 0 to 3 months of life. The course of CNS is progressive, often leading to end-stage renal disease within 2 to 3 years. Most patients with CNS are resistant to glucocorticoids and immunosuppressive drugs. We report a girl aged 1 month and 20 days who was admitted to hospital with a history of abdominal distension and palpebral edema. She was diagnosed with CNS and administered a glucocorticoid (methylprednisolone) for 2 years. Targeted high-throughput next-generation sequencing showed mutations in the NPHS1 gene. She had a favorable outcome after 2 years of treatment. She has remained in complete remission for the last 6 months. From a clinical point of view, the outcome of CNS may be associated with end-stage renal disease or even death. Appropriate pharmacotherapy is beneficial to maintain a normal function and integrity of the glomerular barrier. An aggressive treatment plan is required to save the life of patients with CNS, even if a heterozygous mutation is detected by genetic analysis.

Sign in / Sign up

Export Citation Format

Share Document